Get the Stockscreener App
2.9727
2.91%
-0.0873
Anixa Biosciences Inc stock is traded at $2.9727, with a volume of 110.72K.
It is down -2.91% in the last 24 hours and up +10.45% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$3.06
Open:
$3.05
24h Volume:
110.72K
Relative Volume:
0.92
Market Cap:
$99.41M
Revenue:
$210.00K
Net Income/Loss:
$-10.40M
P/E Ratio:
-9.4401
EPS:
-0.3149
Net Cash Flow:
$-6.88M
1W Performance:
-0.97%
1M Performance:
+10.45%
6M Performance:
-29.09%
1Y Performance:
+14.27%
1-Day Range:
$2.94
$3.10
1-Week Range:
$2.85
$3.1754
52-Week Range:
$2.44
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.965 | 102.60M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
711.31 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.00 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Investing News Network
Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - ChartMill
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ChartMill
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology - marketscreener.com
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - The AI Journal
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Anixa Biosciences receives Mexican patent for breast cancer vaccine - Investing.com
A breast cancer vaccine gained patent protection in Mexico until 2040 - Stock Titan
ANIX Fundamental Analysis & Valuation | Fair Value & Financial Strength | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa’s ovarian cancer therapy to be presented at ISCT meeting By Investing.com - Investing.com India
Anixa’s ovarian cancer therapy to be presented at ISCT meeting - Investing.com
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - ChartMill
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - WFXG
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Yahoo Finance
Weekly Trades: Does Anixa Biosciences Inc have declining or rising EPS2026 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Can Anixa Biosciences Inc maintain its current growth rate2026 Analyst Calls & Consistent Profit Trade Alerts - baoquankhu1.vn
AVAX Technologies and Anixa Biosciences Compared in Critical Analysis - National Today
Earnings Risk: Does Anixa Biosciences Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Anixa Biosciences to Participate in RedChip's Biotech Resurgence - GuruFocus
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Finviz
At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
ANIX Stock: Consistent 'Buy' Rating and Price Target Maintained - GuruFocus
Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 - GuruFocus
Anixa Biosciences to Present at Water Tower Research Insights Conference - National Today
74% vaccine response, CAR-T survival data on Anixa's April 14 agenda - Stock Titan
Breast cancer vaccine hit Phase 1 goals; Anixa cites CAR-T survival data - Stock Titan
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs - ChartMill
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
ANIX Stock Analysis: Anixa Biosciences Inc down 6.25 pct to $2.55 biotech update - Cổng thông tin điện tử tỉnh Lào Cai
Anixa partners with Cytovance for breast cancer vaccine trial By Investing.com - Investing.com South Africa
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 - GuruFocus
Anixa Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results - Oncodaily
Eli Lilly, Space stocks, Anixa Biosciences - TradingView — Track All Markets
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine with New Manufacturing Agreement - GuruFocus
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com
Anixa partners with Cytovance for breast cancer vaccine trial - Investing.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results Cytovance Selected For Cgmp Manufacturing - TradingView
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo Finance
ANIX: Anixa Biosciences Retains 'Buy' Rating with Price Target U - GuruFocus
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):